BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Celltrion readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Celltrion's drugs run\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06939595-2443@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:CT-P51: Phase 3 readout est. (NCT06939595)
DESCRIPTION:CT-P51\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Prev
 iously Untreated Metastatic Lung Cancer\nEstimated primary completion: Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ct-p51#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069395
 95
URL:https://assetmemo.bio/drug/ct-p51#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05906992-7343@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:CT-P53: Phase 3 readout est. (NCT05906992)
DESCRIPTION:CT-P53\, phase 3\, Multiple Sclerosis.\nStudy: A Study to Compa
 re Efficacy\, Pharmacokinetics\, Pharmacodynamics and Safety of CT-P53 and
  Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis\nEstimate
 d primary completion: February 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ct-p53#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05906992
URL:https://assetmemo.bio/drug/ct-p53#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952478-3384@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:CT-P44: Phase 3 readout est. (NCT06952478)
DESCRIPTION:CT-P44\, phase 3\, Multiple Myeloma.\nStudy: A Study to Compare
  Pharmacokinetics\, Efficacy and Safety of Subcutaneous CT-P44 and Darzale
 x Faspro in Combination With Lenalidomide and Dexamethasone in Patients Wi
 th Refractory or Relapsed Multiple Myeloma\nEstimated primary completion: 
 8 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ct-p44#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0695
 2478
URL:https://assetmemo.bio/drug/ct-p44#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
